Insider Trading February 6, 2026

SoFi General Counsel Purchases $105,220 in Stock; Analysts Split After Q4 Beat

Robert S. Lavet adds 5,000 shares to his trust position as SoFi reports Q4 2025 results that beat expectations and draws mixed analyst reactions

By Ajmal Hussain SOFI
SoFi General Counsel Purchases $105,220 in Stock; Analysts Split After Q4 Beat
SOFI

SoFi Technologies general counsel Robert S. Lavet bought 5,000 shares of the company's stock on February 6, 2026, according to a Form 4 filing. The purchase was executed at $21.044 per share for a total of $105,220. Following the transaction, Lavet indirectly holds 17,172 shares through the Robert S. Lavet Trust. The insider move comes after SoFi released fourth-quarter 2025 results that surpassed analyst estimates on both earnings and revenue, prompting a range of analyst responses from upgrades to cautious adjustments in price targets.

Key Points

  • Robert S. Lavet purchased 5,000 shares of SoFi on February 6, 2026, at $21.044 per share, totaling $105,220.
  • Following the transaction, Lavet indirectly holds 17,172 shares via the Robert S. Lavet Trust, where he is beneficiary and trustee.
  • SoFi beat fourth-quarter 2025 expectations: EPS $0.13 versus $0.11 forecast and revenue $1.03 billion versus $973.43 million forecast; analyst reactions were mixed, ranging from upgrades to cautious price-target adjustments.

SoFi Technologies (NASDAQ: SOFI) reported a notable insider purchase and a fourth-quarter performance that outpaced consensus estimates, according to regulatory filings and company results.

On February 6, 2026, Robert S. Lavet, the company's general counsel, acquired 5,000 shares of SoFi common stock at a per-share price of $21.044, for an aggregate transaction value of $105,220. The transaction appears in a Form 4 filed with the Securities and Exchange Commission and shows that Lavet now indirectly holds 17,172 shares through the Robert S. Lavet Trust, in which he is both beneficiary and trustee.

These insider holdings and the recent purchase arrive against the backdrop of SoFi’s fourth-quarter 2025 financial results, which exceeded analyst expectations. The company reported earnings per share of $0.13 versus the consensus forecast of $0.11, and revenue of $1.03 billion compared with the expected $973.43 million.

Analyst reactions to the quarterly beat were mixed. JPMorgan upgraded SoFi’s stock from Neutral to Overweight and set a price target of $31.00. Needham kept its Buy rating intact but lowered its price target to $33.00 from $36.00, citing fintech valuation concerns. Mizuho reiterated an Outperform rating and a $38.00 price target, explicitly recommending investors consider purchases during the current market weakness. Citizens sustained a Market Perform rating while highlighting SoFi’s innovation and customer acquisition advantages.


Context and market signals

The Form 4 filing documents the insider transaction; it confirms Lavet’s addition to his indirect holdings within the trust. The company’s quarterly results, which beat both EPS and revenue expectations, were followed by a spectrum of analyst adjustments that reflect both investor interest and valuation-related caution within the fintech sector.

While the filing and earnings release supply clear data points, the filing itself does not include commentary on Lavet’s motivations or plans for the newly acquired shares.

Risks

  • Fintech valuation concerns cited by Needham could weigh on investor sentiment in financial and fintech markets.
  • Mixed analyst stances and adjusted price targets introduce uncertainty for SoFi’s stock performance in the near term.
  • Recommendations to buy during market weakness and references to current market weakness suggest sensitivity to broader market volatility that could impact financial-sector equities.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026